Records containing: Metastatic Urothelial Carcinoma

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2024-02-29
Multicentric, Observational Study to Evaluate Real World Data of Avelumab in First Line Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma, a SOGUG Study
CLINICAL_TRIALS study record update · 2024-02-15
A Canadian Phase II, Placebo-controlled Randomized Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.
CLINICAL_TRIALS study record update · 2023-11-09
GU-216: A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)
CLINICAL_TRIALS study record update · 2023-08-03
ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MAGE-A1-Specific T-Cell Receptor (TCR) Combined With Atezolizumab in Patients With Metastatic MAGE-A1 Expressing Cancer
CLINICAL_TRIALS study record update · 2023-06-09
Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma After Prior Chemotherapy: a Open-label, Multicenter Phase II Study (UTRUST)
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2023-03-10
Phase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid Cancers
CLINICAL_TRIALS study record update · 2022-12-22
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
CLINICAL_TRIALS study record update · 2022-11-30
An Open Label, Single-arm, Phase 2 Study of Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel in Patients With Metastatic Urothelial Carcinoma After Chemotherapy Failure; the PEANUT Study
CLINICAL_TRIALS study record update · 2022-05-25
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205)
CLINICAL_TRIALS study record update · 2022-04-11
INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
CLINICAL_TRIALS study record update · 2021-12-14
An Open-label, Single-arm, Multi-center, Phase II Clinical Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer
CLINICAL_TRIALS study record update · 2021-09-22
A Phase II Randomized Controlled Trial of Programmed Death -1/Programmed Death Ligand-1(PD-1/PDL-1) Axis Blockade Versus PD-1/PDL-1 Axis Blockade Plus Radiotherapy in Metastatic Genitourinary (Renal/Urothelial) Malignancies
CLINICAL_TRIALS study record update · 2021-05-20
A Phase II Trial to Evaluate Pemetrexed Clinical Responses in Relation to Tumor MTAP Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma
CLINICAL_TRIALS study record update · 2021-02-11
A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients
CLINICAL_TRIALS study record update · 2020-10-19
A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
CLINICAL_TRIALS study record update · 2020-02-17
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
CLINICAL_TRIALS study record update · 2019-09-10
Randomized Phase 2 Trial of ACP-196 and Pembrolizumab Immunotherapy Dual CHECKpoint Inhibition In Platinum Resistant Metastatic Urothelial Carcinoma (RAPID CHECK Study)